LIM and SH3 protein 1 promotes tumor proliferation and metastasis in lung carcinoma

Lin,Xueqiong; Liu,Xianhui; Fang,Yusen; Weng,Xuefen

doi:10.3892/ol.2016.5225

LIM and SH3 protein 1 promotes tumor proliferation and metastasis in lung carcinoma

Authors:
- Xueqiong Lin
- Xianhui Liu
- Yusen Fang
- Xuefen Weng
View Affiliations

Affiliations: Department of Clinical Laboratory, Cancer Hospital of Shantou University Medical College, Shantou, Guangdong 515031, P.R. China, Department of Clinical Laboratory, Meizhou People's Hospital, Meizhou, Guangdong 514031, P.R. China
Published online on: October 5, 2016 https://doi.org/10.3892/ol.2016.5225
Pages: 4756-4760

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is the most frequently diagnosed cancer and the leading cause of cancer-related mortality worldwide. In the present study, we focused on LIM and SH3 protein 1 (LASP-1), a key molecule involved in the development of multiple cancers, and attempted to elucidate its effect on the oncogenesis of lung cancer. We determined the expression level of LASP‑1 in lung cancer using reverse transcription‑quantitative polymerase chain reaction and western blot analysis, and also studied the potential function of LASP‑1 in lung cancer cell growth, apoptosis and migration by small interfering RNA transfection. The results revealed that the levels of LASP‑1 mRNA and protein were abnormally high in lung cancer cells. Following RNA interference of LASP‑1, the proliferation and migration ability of the human cancer cell line A549 were significantly decreased. In addition, fluorescence‑activated cell sorting analysis indicated that the apoptotic process in the A549 cell line was induced by the silencing of LASP‑1. Our study is the first to investigate the potential of LASP‑1 in lung cancer, and revealed its significant role in regulating the growth and metastasis of lung cancer cells. The present study suggests that LASP‑1 has potential as a therapeutic target in the treatment of lung cancer in the clinic.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
2	Singh CR and Kathiresan K: Molecular understanding of lung cancers - a review. Asian Pac J Trop Biomed. 4:(Suppl 1). S35–S41. 2014. View Article : Google Scholar : PubMed/NCBI
3	Novaes FT, Cataneo DC, Junior RL Ruiz, Defaveri J, Michelin OC and Cataneo AJM: Lung cancer: histology, staging, treatment and survival. J Bras Pneumol. 34:595–600. 2008.(In English and Portuguese). View Article : Google Scholar : PubMed/NCBI
4	Youlden DR, Cramb SM and Baade PD: The international epidemiology of lung cancer: geographical distribution and secular trends. J Thorac Oncol. 3:819–831. 2008. View Article : Google Scholar : PubMed/NCBI
5	Johnson JL, Pillai S and Chellappan SP: Genetic and biochemical alterations in non-small cell lung cancer. Biochem Res Int. 2012:9404052014.
6	Rodenhuis S, Slebos RJ, Boot AJ, Evers SG, Mooi WJ, Wagenaar SS, van Bodegom PC and Bos JL: Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res. 48:5738–5741. 1988.PubMed/NCBI
7	Liu H, Radisky DC, Yang D, Xu R, Radisky ES, Bissell MJ and Bishop JM: MYC suppresses cancer metastasis by direct transcriptional silencing of αv and β3 integrin subunits. Nat Cell Biol. 14:567–574. 2012. View Article : Google Scholar : PubMed/NCBI
8	Prins J, De Vries EG and Mulder NH: The myc family of oncogenes and their presence and importance in small-cell lung carcinoma and other tumour types. Anticancer Res. 13:1373–1385. 1993.PubMed/NCBI
9	Kurup A and Hanna NH: Treatment of small cell lung cancer. Crit Rev Oncol Hematol. 52:117–126. 2004. View Article : Google Scholar : PubMed/NCBI
10	Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J and Johnson DH: Eastern Cooperative Oncology Group: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 346:92–98. 2002. View Article : Google Scholar : PubMed/NCBI
11	Kumarakulasinghe NB, van Zanwijk N and Soo RA: Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC). Respirology. 20:370–378. 2015. View Article : Google Scholar : PubMed/NCBI
12	Chew CS, Chen X, Parente JA, Tarrer S, Okamoto C and Qin HY: Lasp-1 binds to non-muscle F-actin in vitro and is localized within multiple sites of dynamic actin assembly in vivo. J Cell Sci. 115:4787–4799. 2002. View Article : Google Scholar : PubMed/NCBI
13	Nakagawa H, Terasaki AG, Suzuki H, Ohashi K and Miyamoto S: Short-term retention of actin filament binding proteins on lamellipodial actin bundles. FEBS Lett. 580:3223–3228. 2006. View Article : Google Scholar : PubMed/NCBI
14	Grunewald TG, Kammerer U, Schulze E, Schindler D, Honig A, Zimmer M and Butt E: Silencing of LASP-1 influences zyxin localization, inhibits proliferation and reduces migration in breast cancer cells. Exp Cell Res. 312:974–982. 2006. View Article : Google Scholar : PubMed/NCBI
15	Zhao L, Wang H, Liu C, Liu Y, Wang X, Wang S, Sun X, Li J, Deng Y, Jiang Y and Ding Y: Promotion of colorectal cancer growth and metastasis by the LIM and SH3 domain protein 1. Gut. 59:1226–1235. 2010. View Article : Google Scholar : PubMed/NCBI
16	Salvi A, Bongarzone I, Miccichè F, Arici B, Barlati S and De Petro G: Proteomic identification of LASP-1 down-regulation after RNAi urokinase silencing in human hepatocellular carcinoma cells. Neoplasia. 11:207–219. 2009. View Article : Google Scholar : PubMed/NCBI
17	Wang H, Li W, Jin X, Cui S and Zhao L: LIM and SH3 protein 1, a promoter of cell proliferation and migration, is a novel independent prognostic indicator in hepatocellular carcinoma. Eur J Cancer. 49:974–983. 2013. View Article : Google Scholar : PubMed/NCBI
18	Chiyomaru T, Enokida H, Kawakami K, Tatarano S, Uchida Y, Kawahara K, Nishiyama K, Seki N and Nakagawa M: Functional role of LASP1 in cell viability and its regulation by microRNAs in bladder cancer. Urol Oncol. 30:434–443. 2012. View Article : Google Scholar : PubMed/NCBI
19	Butt E, Gambaryan S, Göttfert N, Galler A, Marcus K and Meyer HE: Actin binding of human LIM and SH3 protein is regulated by cGMP-and cAMP-dependent protein kinase phosphorylation on serine 146. J Biol Chem. 278:15601–15607. 2003. View Article : Google Scholar : PubMed/NCBI
20	Li B, Zhuang L and Trueb B: Zyxin interacts with the SH3 domains of the cytoskeletal proteins LIM-nebulette and Lasp-1. J Biol Chem. 279:20401–20410. 2004. View Article : Google Scholar : PubMed/NCBI
21	Schreiber V, Moog-Lutz C, Régnier CH, Chenard MP, Boeuf H, Vonesch JL, Tomasetto C and Rio MC: Lasp-1, a novel type of actin-binding protein accumulating in cell membrane extensions. Mol Med. 4:675–687. 1998.PubMed/NCBI
22	Chew CS, Parente JA Jr, Zhou CJ, Baranco E and Chen X: Lasp-1 is a regulated phosphoprotein within the cAMP signaling pathway in the gastric parietal cell. Am J Physiol. 275:C56–C67. 1998.PubMed/NCBI
23	Wei CL, Wu Q, Vega VB, Chiu KP, Ng P, Zhang T, Shahab A, Yong HC, Fu Y, Weng Z, et al: A global map of p53 transcription-factor binding sites in the human genome. Cell. 124:207–219. 2006. View Article : Google Scholar : PubMed/NCBI
24	Pfeifer GP, Denissenko MF, Olivier M, Tretyakova N, Hecht SS and Hainaut P: Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene. 21:7435–7451. 2002. View Article : Google Scholar : PubMed/NCBI
25	Wang B, Feng P, Xiao Z and Ren EC: LIM and SH3 protein 1 (Lasp1) is a novel p53 transcriptional target involved in hepatocellular carcinoma. J Hepatol. 50:528–537. 2009. View Article : Google Scholar : PubMed/NCBI